2020 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
2020 Report on TB Research Funding Trends
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.
TAGline November 2020
'The Struggle of a Lifetime' (Continued): The words of the late Honorable John Lewis ring powerfully true today. In the U.S., as we welcome a new President-elect and Vice President-elect, we must also defend democracy to ensure a complete, peaceful transition of power. We engage in the struggles generations before us have advanced, despite myriad challenges and emerging new threats such as COVID-19.
Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement
Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.
TAG Welcomes the Election of Joseph R. Biden Jr. and Kamala D. Harris
Treatment Action Group (TAG) congratulates President-elect Joe Biden and Vice President-elect Kamala Harris on their ascension to the highest offices of the United States. Their victory in both the popular and electoral vote is historic.
Letter to Special Rapporteur on Cultural Rights
Our current letter follows an earlier letter dated June 23, 2020 and calls on the Special Rapporteur for cultural rights to explicitly acknowledge the human rights dimensions of science and reaffirm the right of everyone to participate in and enjoy the benefits of scientific progress and its applications in her forthcoming communication with the United Nations General Assembly on COVID-19.
Finally—A New Four-Month Treatment for Drug-Susceptible TB!
Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months.
Por fin un nuevo tratamiento de cuatro meses para la tuberculosis sensible a fármacos
El Grupo de Acción para el Tratamiento (TAG, por sus siglas en inglés) y el Grupo de Asesores Comunitarios de Investigación (CRAG, por sus siglas en inglés) se congratulan ante la noticia de un régimen seguro y eficaz capaz de acortar el tratamiento de la tuberculosis (TB) a sólo cuatro meses.
Research in Action Awards 2020
Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost, and recognize champions of progress and justice.
Advancing Access through Market Interventions: Lessons Learned from the GeneXpert Tuberculosis Test Buy-Down
This policy brief examines lessons learned from the Xpert MTB/RIF TB test buy-down and provides recommendations and pro-access conditions that should be applied to R&D funding, buy-down, and other market intervention agreements for COVID-19 diagnostics.